Quality CLEEN

Automated HBEL-Based Cleaning Limit Lifecycle

Leucine CLEEN replaces the spreadsheet-driven cleaning validation lifecycle with a structured, audit-ready system. It ingests toxicological data, calculates health-based exposure limits (HBELs) and maximum allowable carryover (MACO) for every product-equipment combination, generates worst-case matrices that update automatically when products are added or removed, and produces risk-based protocols with defensible acceptance criteria. Every calculation is traceable, every matrix is current, and every protocol is audit-ready.

Key Highlights

01 HBEL/PDE-based limit calculations with full toxicological traceability
02 Worst-case product matrices that update automatically with portfolio changes
03 Risk-based protocol generation with defensible acceptance criteria
04 Continuous lifecycle monitoring across all product-equipment combinations

Regulatory Context

What FDA Inspectors Cite

21 CFR 211.67 Worst-Case Selection
1 / 6

Worst-case contaminants not considered for multi-use filling equipment — swab sampling excluded critical surfaces

Cleaning validation studies for multi-use filling equipment failed to consider all worst-case contaminants, including a compound used in the stopper processing step. Swab sampling excluded small-outlet surfaces that represented harder-to-clean geometries than those actually sampled. Limits of detection were not provided in the validation report for residual active testing.

Jiangsu Hengrui Pharmaceuticals Co., Ltd · 2024-01-16
21 CFR 211.67 Validation Gap
2 / 6

Cleaning of non-dedicated equipment not validated — visible residue found despite equipment being marked clean

Cleaning validation had not been performed for non-dedicated equipment used to manufacture US market products. During an inspection walkthrough, what appeared to be product residue was observed on equipment surfaces despite the equipment being identified as "clean" in the system. The firm failed to demonstrate that cleaning procedures were effective in preventing cross-contamination between different batches.

Fareva Amboise · 2025-09-16
21 CFR 211.67 Sampling Deficiency
3 / 6

Swab sampling not performed during cleaning validation of multi-product equipment — carryover risk unassessed

Cleaning validation for product-contact process equipment lacked swab sampling on multiple surfaces during validation runs. The firm could not demonstrate that cleaning procedures were effective in preventing product carryover and cross-contamination between different products manufactured on the same equipment lines.

Sanofi-Aventis Deutschland GmbH · 2025-01-16
21 CFR 211.67 Cross-Contamination
4 / 6

Non-dedicated equipment not adequately cleaned — cross-contamination between drug products on shared lines

Non-dedicated manufacturing equipment was not adequately cleaned between product campaigns. Routine cleaning procedures failed to prevent cross-contamination between different drug products processed on shared equipment. The cleaning validation programme did not establish that the procedures were effective for all product-equipment combinations in the manufacturing matrix.

Otsuka Pharmaceutical Co., Ltd. · 2024-03-22
21 CFR 211.67 Equipment Maintenance
5 / 6

Equipment cleaning in API production not maintained to prevent contamination — non-dedicated equipment used across US products

Non-dedicated production equipment used to manufacture US market API products was found in conditions that could alter product safety, identity, strength, quality, or purity. Cleaning and maintenance procedures were not adequate to prevent contamination between different API manufacturing campaigns in the same facility.

Alembic Pharmaceuticals Limited (Units I and II) · 2025-05-31
21 CFR 211.67 Hazardous API Risk
6 / 6

Cleaning process not validated for non-dedicated equipment — no assurance of cross-contamination prevention between hazardous APIs

Equipment cleaning had not been validated for non-dedicated equipment used to process multiple hazardous APIs. The firm could not provide evidence that cross-contamination between different active pharmaceutical ingredients was prevented. Cleaning documentation lacked the detail necessary to demonstrate that validated limits were achieved consistently.

F.H. Investments Inc. · 2024-11-08

The Problem

Why Cleaning Validation Programmes Fall Behind

Challenge 1 1 / 6

HBEL Calculations Bottlenecked by Toxicology

  • A single HBEL calculation requires review of 15-20 toxicological endpoints per compound
  • New product introductions wait weeks for toxicology review before cleaning limits can be set
  • Contract toxicology services charge per compound with 4-8 week turnaround times
Challenge 2 2 / 6

Worst-Case Matrices Are Static and Stale

  • A typical multi-product facility has 50-200 product-equipment combinations to evaluate
  • Adding one new product requires recalculating the entire matrix to determine if the worst case changes
  • Most facilities discover their matrix is outdated only when an inspector asks to see it
Challenge 3 3 / 6

Protocol Generation Takes Weeks Per Equipment Train

  • Protocol writers spend 2-3 weeks per equipment train assembling data from multiple spreadsheets
  • Acceptance criteria must be recalculated from HBEL data for each product-surface combination
  • Errors in manual MACO calculations have resulted in limits that are orders of magnitude wrong
Challenge 4 4 / 6

No Lifecycle Monitoring After Initial Validation

  • New PDE values published in peer-reviewed literature are not systematically tracked against existing limits
  • Product portfolio changes at multi-site companies are not propagated to cleaning validation programmes at all sites
  • Revalidation triggers are discovered reactively — usually during an audit or inspection
Challenge 5 5 / 6

Multi-Site Inconsistency in Limit Methodologies

  • Acquired facilities often bring legacy dose-based limits that conflict with the parent company approach
  • No centralised system tracks which methodology each facility uses for each product
  • Auditors at multi-site companies find 3-4 different limit calculation approaches across their network
Challenge 6 6 / 6

Audit Trail Gaps in Spreadsheet-Based Calculations

  • Spreadsheets are emailed between toxicologists, validation scientists, and QA with no version control
  • There is no electronic signature trail showing who calculated, reviewed, and approved each limit
  • During inspections, companies cannot demonstrate the calculation history for a given cleaning limit

Cleaning Limit Lifecycle in Leucine CLEEN

1

Toxicological Data Ingestion & HBEL Calculation

Leucine CLEEN ingests toxicological data for every product in your portfolio — PDE values, ADE values, OEL classifications, solubility profiles, and therapeutic doses. The system calculates health-based exposure limits using the standard EMA/ISPE methodology, with full traceability from source data to final limit.

PDE/ADE Extraction HBEL Derivation Solubility Classification Source Traceability

Toxicology Sources

PDE Values
ADE/OEL Data
Solubility Profiles
Therapeutic Doses

CLEEN Engine

HBEL Derivation
MACO Calculation
Safety Factor Application

Output

Product HBEL Register
Limit Audit Trail
2

Worst-Case Product Matrix Generation

CLEEN automatically generates the worst-case product matrix for every equipment train in your facility. It evaluates every product-equipment combination against HBEL-derived limits, solubility, cleaning difficulty, and surface area to identify the true worst case — not the assumed one.

Product-Equipment Mapping Worst-Case Ranking MACO per Surface Area Automatic Re-evaluation
3

Risk-Based Protocol Design

For each equipment train, CLEEN generates a cleaning validation protocol driven by the worst-case matrix. Sampling plans are designed based on equipment geometry, surface characteristics, and hard-to-clean areas. Acceptance criteria are calculated directly from HBEL-derived MACO values — not manually transcribed from spreadsheets.

Sampling Point Selection Acceptance Criteria Calculation Recovery Factor Application Protocol Document Generation
4

Equipment Grouping & Bracketing

CLEEN analyses equipment across your facility — and across sites — to identify groups with similar design, cleaning difficulty, and product contact characteristics. Bracketing strategies reduce validation scope without compromising scientific rigour, with defensible grouping rationale documented automatically.

Design Similarity Analysis Cleaning Difficulty Ranking Bracketing Strategy Scope Optimisation
5

Continuous Lifecycle Monitoring

After initial validation, CLEEN continuously monitors the cleaning validation lifecycle. When a new product is introduced, a product is discontinued, new toxicological data is published, or equipment is modified, the system automatically flags affected matrices, recalculates limits, and identifies protocols that require revalidation.

Change Impact Assessment Limit Recalculation Revalidation Triggering Multi-Site Propagation
6

Audit-Ready Compliance Packages

CLEEN compiles audit-ready documentation packages — HBEL calculation summaries, worst-case rationale, validation protocols, execution results, and lifecycle change history — in FDA and EMA-formatted reports. One-click export produces the complete cleaning validation package for any product, equipment train, or facility.

Regulatory Format Templates Cross-Reference Assembly Evidence Packaging Multi-Site Rollup

The Solution

How Leucine Solves This

Purpose-built cleaning validation lifecycle management — from toxicological data to audit-ready packages — addressing both the regulatory gaps and the operational bottlenecks.

CLEEN Validation Engine

HBEL-Based Limit Calculations with Full Traceability

CLEEN calculates health-based exposure limits using structured toxicological data, generates MACO values for every product-equipment combination, and maintains a complete audit trail from source data to final limit. When toxicological data is updated, affected limits are automatically recalculated.

  • Structured HBEL/PDE/ADE calculations with EMA/ISPE methodology
  • Automatic MACO derivation for every product-surface combination
  • Source-to-limit traceability for every calculation step
CLEEN Matrix & Protocol Manager

Dynamic Worst-Case Matrices and Risk-Based Protocol Generation

Worst-case product matrices are generated and maintained automatically — evaluated against HBEL-derived limits, solubility, cleaning difficulty, and equipment geometry. Protocols are auto-generated with sampling plans, acceptance criteria, and analytical methods linked directly to the matrix data.

  • Automatic worst-case ranking across all product-equipment combinations
  • Risk-based sampling plan design based on equipment geometry and hard-to-clean areas
  • Acceptance criteria calculated directly from HBEL data — no manual transcription
LeucineOS Enterprise Platform

Multi-Site Harmonisation with 21 CFR Part 11 Compliance

CLEEN operates on the LeucineOS platform, providing enterprise-wide visibility into cleaning validation status across all facilities. A single methodology, a single data model, and a single audit trail — harmonised across sites and regulatory jurisdictions.

  • Centralised cleaning validation lifecycle across all manufacturing sites
  • Full 21 CFR Part 11 compliance — electronic signatures, audit trails, version control
  • Cross-site impact assessment when portfolio or methodology changes occur
FDA Tracker

Cleaning Validation Enforcement Intelligence

FDA Tracker monitors cleaning validation-related 483 observations and warning letters across the industry, identifying trends in what inspectors are citing and how regulatory expectations are evolving. Quality teams see which facilities in their peer group are being cited for cleaning validation gaps.

  • Real-time monitoring of cleaning validation 483s and warning letters
  • Trend analysis showing evolving FDA expectations for HBEL-based limits
  • Peer benchmarking against facilities with similar product portfolios

Before & After

The Shift

Dimension
Spreadsheet-Based
Leucine CLEEN
Limit calculations
Manual HBEL derivation in Excel — 4-8 weeks per product via contract toxicology
Structured HBEL calculations with source traceability, completed in hours
Worst-case matrix
Static spreadsheet built once, rarely updated when portfolio changes
Dynamic matrix that recalculates automatically with every product or equipment change
Protocol generation
2-3 weeks per equipment train, manual data assembly from multiple spreadsheets
Auto-generated protocols with acceptance criteria calculated directly from HBEL data
Lifecycle monitoring
None — revalidation triggers discovered during audits or inspections
Continuous monitoring flags affected validations when products, limits, or equipment change
Multi-site consistency
3-4 different methodologies across facilities, no centralised oversight
Single platform, single methodology, harmonised limits across all sites
Audit readiness
Weeks to compile documentation from scattered files and emails
One-click audit packages with full calculation traceability and lifecycle history

Results

Measurable Impact

Results from pharmaceutical manufacturers using Leucine CLEEN for cleaning validation lifecycle management.

80%
Validation Cycle Time
Faster cleaning validation cycles — from months to weeks per equipment train
100%
Calculation Errors
Elimination of manual calculation errors in HBEL, MACO, and acceptance criteria
0
Paper-Based Protocols
Paper-based protocols remaining — fully digital lifecycle with 21 CFR Part 11 compliance
7+
Facilities Harmonised
Manufacturing facilities operating on a single, harmonised cleaning validation methodology

Next Step

Get Started

Stop managing cleaning validation in spreadsheets that cannot be audited, cannot enforce lifecycle monitoring, and cannot scale across sites. Leucine CLEEN provides the structured HBEL-based lifecycle that regulatory expectations now demand — from toxicological data to audit-ready packages, across every facility.

Get Started
Exit